BSETrident Texofab LtdMediumNeutral
Announced Thu, 14 Aug · 18:54 IST

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the quarter ended June 30, 2025.

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab reported Q1FY26 revenue from operations of ₹2,807.68 Lakhs, up 9% YoY from ₹2,571.21 Lakhs. EBITDA grew 36% YoY to ₹206.40 Lakhs, with margins expanding to 7.35% from 5.92% in Q1FY25 (a 143 basis points improvement) and 3.55% in Q4FY25. Profit after tax rose 46% YoY to ₹101.59 Lakhs, aided by a 31% YoY decline in interest costs. The manufacturing vertical contributed 65.9% of revenue, with management noting their 'Shifting Gears' strategy toward higher-margin manufacturing operations and referencing a recent capital infusion to support future growth.

Likely market impact

Strong margin expansion of over 143 bps YoY and a nearly 50% jump in profits signal a meaningful operational turnaround and may be viewed positively by investors, though the sustainability of these margins given FY25's full-year EBITDA margin of just 4.48% remains a watchpoint.